Larry Glass - Neuren Pharmaceuticals Insider

NURPF -- USA Stock  

USD 0.91  0.02  2.15%

  CEO
Mr. Larry Glass was Chief Science Officer and Executive Director of Neuren Pharmaceuticals Limited since September 2, 2013. He is a seasoned manager with more than 30 years in the life sciences industry. Before he joined Neuren, he worked as an independent consultant for a number of biotech companies in the US and internationally, providing management, strategic and business development services. Prior to that, he was CEO of a contract research organisation that provided preclinical research and clinical trials support for major pharmaceutical and biotechnology companies and the US government. For a number of years, the CRO operated as a subsidiary of a NYSElisted company and was subsequently sold to a European biopharmaceutical enterprise which was then acquired by Johnson Johnson.
  CEO Since 2013      
61 3 9092 0480  http://www.neurenpharma.com

Management Efficiency

The company has return on total asset (ROA) of (39.89) % which means that it has lost $39.89 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 29.66 % meaning that it generated $29.66 on every $100 dollars invested by stockholders.

Similar Executives

Found 6 records

CEO Since

George ScangosBiogen
N/A
Lars SoerensenNovo Nordisk AS
2015
Paul PerreaultCSL Limited
2013
Perry KarsenCelgene Corporation
N/A
Flemming OrnskovShire plc
2013
Leonard SchleiferRegeneron Pharmaceuticals
1994

Entity Summary

Neuren Pharmaceuticals Limited, a biopharmaceutical company, engages in the development of therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Auckland, New Zealand. Neuren Pharmaceuticals is traded on OTC Market in USA.Neuren Pharmaceuticals Limited (NURPF) is traded on OTC Market in USA. It is located in PWC Tower and employs 10 people.

Neuren Pharmaceuticals Leadership Team

Joseph Horrigan, VP of Clinical Devel. and Medical Affairs
Larry Glass, CEO, Managing Director
Bruce Hancox, Independent Non-Executive Director
Jenny Harry, Non-Executive Independent Director
James Shaw, COO
Patrick Davies, Non-Executive Independent Director
Dianne Angus, Non-Executive Independent Director
Richard Treagus, Executive Chairman of the Board
Trevor Scott, Independent Non-Executive Director
Jon Pilcher, CFO, Company Secretary

Stock Performance Indicators

Did you try this?

Run Portfolio File Import Now

   

Portfolio File Import

Quickly import all of your third-party portfolios from your local drive in csv format
All  Next Launch Portfolio File Import

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Search macroaxis.com